Selected Publications
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia Am J Hematol : 2023.
Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH: The New NCI Precision Medicine Trials Clin Cancer Res : 2023.
Chippendale L, Freyer CW, Carulli A, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, Porter DL, Stadtmauer EA, Loren AW: One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant J Oncol Pharm Pract : 2023.
Foran JM, Sun Z, Lai C, Fernandez HF, Cripe LD, Ketterling RP, Racevskis J, Luger SM, Paietta E, Lazarus HM, Zhang Y, Bennett JM, Levine RL, Rowe JM, Litzow MR, Tallman MS: Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. Cancer : 2023.
Schwab RD, Luger SM: Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia? Curr Treat Options Oncol. : 2023.
Zarnegar-Lumley S, Alonzo T, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti AR, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer KM, Tallman MS, Litzow MR, Atallah E, Cooper TM, Aplenc R, Abdel-Wahab OI, Gamis AS, Luger SM, Erba HP, Levine RL, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K.: Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, ECOG analysis Blood Adv : 2023.
Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies Transplant Cell Ther : 2023.
Burkard T, Herrero San Juan M, Dreis C, Kiprina A, Namgaladze D, Siebenbrodt K, Luger S, Foerch C, Pfeilschifter JM, Weigert A, Radeke HH: Differential expression of CD8 defines phenotypically distinct cytotoxic T cells in cancer and multiple sclerosis Clin Transl Med : 2022.
Ganzel C, Sun Z, Baslan T, Zhang Y, Gönen M, Abdel-Wahab OI, Racevskis J, Garrett-Bakelman F, Lowe SW, Fernandez HF, Ketterling R, Luger SM, Litzow M, Lazarus HM, Rowe JM, Tallman MS, Levine RL, Paietta E.: Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling Leuk Res 123 : 106971,2022.
Lockwood BJ, El-Jawahri A, Walker AR, Ehrman S, Russell D, Kale SS, Gustin J, Bose-Brill S, LeBlanc TW, Luger SM, Lustberg M, Bhatnagar B.: Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy J Adolesc Young Adult Oncol : 2022.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-614-1847
Patient appointments: 800-789-7366